Cogent Biosciences, Inc. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

Clasificación en acciones #3343
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Precio por acción
$30.11
Capitalización bursátil
$5.22B
Cambio (1 día)
2.00%
Cambio (1 año)
83.71%
País
US
Comercio Cogent Biosciences, Inc. (COGT)

Categoría

Healthcare
Historial de dividendos de Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (símbolo bursátil: COGT) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Cogent Biosciences, Inc. (COGT) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL